Market Place
Sourcing Support
Aurinia Presents LUPKYNIS Data At ASN Kidney Week 2024
11 Oct 2024 //
BUSINESSWIRE
Aurinia Announces Japan Approval of LUPKYNIS® for Lupus Nephritis
24 Sep 2024 //
BUSINESSWIRE
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
13 Sep 2024 //
BUSINESSWIRE
Aurinia Announces Board Restructuring
12 Sep 2024 //
BUSINESSWIRE
Aurinia: LUPKYNIS Profile In Lupus Nephritis At EULAR 2024
05 Jun 2024 //
BUSINESSWIRE
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
07 May 2024 //
BUSINESSWIRE
Aurinia brings singer Toni Braxton to Lupus Awareness Month push
01 May 2024 //
FIERCE PHARMA
FDA Approves Updated LUPKYNIS® Label With Long-Term AURORA Data
30 Apr 2024 //
BUSINESSWIRE
Otsuka Submits New Drug Application in Japan for Voclosporin
10 Nov 2023 //
PRESS RELEASE
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) a
20 Jun 2023 //
BUSINESSWIRE
LUPKYNIS Achieved Higher Renal Response in Lupus Nephritis Patients
01 Jun 2023 //
BUSINESSWIRE
Otsuka announces NICE recommendation of Lupkynis® (voclosporin)
03 May 2023 //
BUSINESSWIRE
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS®
03 May 2023 //
BUSINESSWIRE
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
02 May 2023 //
BUSINESSWIRE
Aurinia Announces New and Refined Method of Use Patent for LUPKYNIS
11 Apr 2023 //
BUSINESSWIRE
Aptalis Pharma`s Lupkynis (Voclosporin) Approved In Europe
07 Feb 2023 //
EMA
Aurinia Announces Allowance of a New & Refined Method of Use Patent for LUPKYNIS
24 Jan 2023 //
BUSINESSWIRE
Major Shifts in Management of Patients with Lupus Nephritis Spurred
20 Jan 2023 //
PR NEWSWIRE
Aurinia Announces LUPKYNIS®Patent Challenge Settlement Reached With Sun Pharma
03 Jan 2023 //
BUSINESSWIRE
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS®
30 Nov 2022 //
BUSINESSWIRE
Otsuka`s Lupkynis (voclosporin) Receives Approval in Europe
20 Sep 2022 //
EMA
Otsuka announces EC approval of Lupkynis®? (voclosporin)
20 Sep 2022 //
PHARMIWEB
Aurinia Announces European Commission Approval of LUPKYNIS®
19 Sep 2022 //
BUSINESSWIRE
Aurinia Announces European Commission Approval of LUPKYNIS (voclosporin)
19 Sep 2022 //
PRESS RELEASE
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 //
BUSINESSWIRE
Aurinia Announces Positive CHMP Opinion for LUPKYNIS in ALN
22 Jul 2022 //
BUSINESSWIRE
Aurinia Presents Data Demonstrating LUPKYNIS is Effective in Lupus Nephritis
03 Jun 2022 //
BUSINESSWIRE
Aurinia Shows +ve Topline Results From AURORA 2 Continuation Study of LUPKYNIS
09 Dec 2021 //
BUSINESSWIRE
Acquisition Rumors Continue to Circulate Around Aurinia as GSK Denies Interest
01 Nov 2021 //
BIOSPACE
Aurinia Announces Updated Interim Results AURORA 2 Continuation Study LUPKYNIS
01 Nov 2021 //
PRESS RELEASE
Aurinia Pharmaceuticals to Present 5 Abstracts at ASN Kidney Week 2021 and ACR
26 Oct 2021 //
YAHOO
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin)
08 Apr 2021 //
BUSINESSWIRE
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin
15 Dec 2020 //
PRESS RELEASE
Aurinia initiates voclosporin trial in KTRs with Covid-19
28 Oct 2020 //
CLINICALTRIALSARENA
Aurinia Announces European Investigator-Initiated Trial Voclosporin
27 Oct 2020 //
BUSINESSWIRE
Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Analysis
23 Oct 2020 //
PRESS RELEASE
ICER to Assess Treatments for Lupus Nephritis
10 Aug 2020 //
ICER
Aurinia Completes Patient Enrollment Into the AUDREY Ph 2/3 Trial Voclosporin
22 Jun 2020 //
BUSINESSWIRE
Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020
05 Jun 2020 //
PRESS RELEASE
Aurinia Completes Submission of New Drug Application to the USFDA
26 May 2020 //
AURINIAPHARMA
Aurinia Initiates Rolling Sub of a NDA to USFDA Administration for Voclosporin
16 Mar 2020 //
BUSINESSWIRE
Aurinia soars as phase 3 lupus study hits primary endpoint
05 Dec 2019 //
FIERCE BIOTECH
Aurinia Announces Positive AURORA Phase 3 Trial Results
04 Dec 2019 //
BUSINESS INSIDER
Aurinia starts voclosporin dosing in Phase II/III study
01 Nov 2019 //
CLINICALTRIALSARINA
Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study
16 Oct 2019 //
BUSINESSWIRE
Aurinia Initiates Phase 2 Clinical Trial for the Treatment of Dry Eye Syndrome
11 Jul 2018 //
BUSINESSWIRE
Canadian Lupus drug to enter Phase III with Worldwide Clinical Trials
30 Jan 2017 //
OUTSOURCING PHARMA
Lonza Contracted to make API for Aurinia`s Lupus Nephritis Candidate
22 Dec 2016 //
IN PHARMATECHNOLOGIST
Aurinia Pharmaceuticals Has Great Upside Potential Entering Phase 3 Trial
10 Nov 2016 //
SEEKING ALPHA
Aurinia Has FDA OK For Phase III Voclosporin Trialing In Lupus Nephritis
04 Nov 2016 //
SRIP
Lupus Research Alliance Welcomes Voclosporin Trial Results
23 Aug 2016 //
PR NEWSWIRE
Aurinia`s Voclosporin Meets Primary Endpoint in Phase IIB
15 Aug 2016 //
BIOSPACE
Voclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted
16 Jun 2016 //
BUSINESSWIRE
